A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma
Plain-language summary
This NA trial is studying Microdevices, Standard of care therapy, and other medications for people with cutaneous T-cell lymphoma (skin lymphoma). Patients are randomly assigned to different treatment groups to see which approach works best. It is available at 1 US location.
Who can join (key eligibility)
- Age 18 Years or older
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Microdevices (DEVICE): The microdevice was developed as a tool with the ultimate goal to help screen several existing and investigational drugs directly within a patient's tumor to identify what drugs are the most effective for treating a patient's cancer. | Standard of care therapy (OTHER): Participant to receive standard of care therapy as previously determined by participant's treating oncologist and/or dermatologist, which may include a skin-directed or systemic therapy | Standard of care systemic therapy (OTHER): Participant to receive standard of care therapy as previously determined by participant's treating oncologist and/or dermatologist, which must include a systemic therapy.
- Drugs / treatments
- Microdevices, Standard of care therapy, Standard of care systemic therapy
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details